Contact Us

Global Yervoy Insights 2025, Forecast To 2034

7 Mar, 2025

What Has Been The Evolution of the Yervoy Market in Recent Years?

The yervoy market has seen considerable growth due to a variety of factors.
• The market size of Yervoy has seen a swift expansion in the previous years. It is predicted to rise from $5,420 million in 2024 to $6,010 million in 2025, reflecting a compound annual growth rate (CAGR) of 10.9%.
The surge in growth during the historic period is due to factors like rising cancer occurrences, an escalating emphasis on combination therapies, approval of new indications by the regulatory authority, advancements in biological production, and augmented investment in oncology research.

What Is the Forecasted Market Size and Growth Rate for The Yervoy Market Size In The Coming Years?

The yervoy market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for a swift expansion in the Yervoy market size in the coming years with projected growth to $9,000 million in 2029 with a compound annual growth rate (CAGR) of 10.6%.
This predicted growth during the forecast period is due to factors such as rising customer demands in developing markets, broadening of industrial applications, advancements in clinical studies, increased biologics investments, and worldwide market expansion. Significant trends during this period will include the proliferation of combined immunotherapies, the widening of indications for new cancer, improvements in the delivery systems of biologic drugs, greater integration of Artificial Intelligence (AI) in oncology, and a more patient-focused approach to drug development.

What Factors Are Driving Growth In The Yervoy Market?

The rise in melanoma occurrences is forecasted to drive the expansion of the yervoy market. Melanoma, a form of skin cancer, originates within melanocytes that produce melanin, the pigment that determines skin color. The escalating rate of melanoma is attributed to factors such as increased sun exposure, lifestyle modifications, and UV radiation from ozone layer depletion. Heightened awareness and better diagnostic methods are also leading to a larger number of detections. Yervoy, which targets the CTLA-4 protein, amplifying the immune system's capability to identify and combat cancer cells, has shown significant benefits for those suffering from melanoma, enhancing survival rates and prolonged responses, even in advanced stages of the disease. The American Cancer Society, a US non-profit organization committed to eradicating cancer, reported in January 2024 that around 100,640 fresh cases of melanoma are anticipated to be identified in the USA in 2024, with 59,170 male and 41,470 female cases respectively. The organization also expects approximately 8,290 fatalities from melanoma in 2024, affecting 5,430 men and 2,860 women. Hence, the escalating rate of melanoma is fueling the growth of the yervoy market.

What Are The Main Segments Of The Global Yervoy Market?

The yervoy market covered in this report is segmented –
1) By Type: 40 ml, 10 ml
2) By Clinical Indication: Melanoma, Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Colorectal Cancer (CRC)
3) By Distribution Channel: Hospitals, Oncology Clinics, Retail Pharmacies, Online Pharmacies
4) By End User: Adult, Geriatric

Pre-Book The Yervoy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:

What Emerging Trends Are Influencing The Growth Of The Yervoy Market?

Focusing on the creation of innovative combination therapies is the primary trend in the Yervoy market. The strategy is aimed at enhancing treatment effectiveness and expanding the scope for cancer indications. One such combination is Opdivo (nivolumab) and Yervoy (ipilimumab), which synergistically amplifies the immune response by targeting complementing immune checkpoint pathways. This increases the effectiveness in combating a variety of cancers like melanoma and renal cell carcinoma. For example, in June 2024, notable results from the CheckMate-9DW trial were announced by US-based pharmaceutical manufacturing company Bristol Myers Squibb. This trial evaluated the effectiveness of the combined use of Opdivo and Yervoy as an initial treatment for patients with advanced hepatocellular carcinoma (HCC). It concluded that this dual immunotherapy regimen significantly enhanced overall survival rates, as opposed to standard treatments like lenvatinib or sorafenib. A statistically significant improvement in overall survival was observed in patients with advanced HCC who were treated with the combination of Opdivo and Yervoy, compared to those treated with lenvatinib or sorafenib only.

Who Are the Key Players In The Yervoy Market?

Major companies operating in the yervoy market include:
• Bristol-Myers Squibb
• Merck & Co.
• Ono Pharmaceutical

What Is The Most Dominant Region In The Yervoy Market?

North America was the largest region in the yervoy market in 2024. The regions covered in the yervoy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.